This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

OBN Facilitates Funding To UK R&D Companies From The Biomedical Catalyst Scheme

ABINGDON, England, November 8, 2012 /PRNewswire/ --

OBN, the trade association for emerging life sciences companies, is gratified to note the recent £39 million tranche in funding awards to UK life science companies under the Biomedical Catalyst Scheme administered by the Technology Strategy Board (TSB). 

Since March 2012, OBN has held four events in Oxford, Cambridge and London where over 220 attendees from life science companies were able to meet, interact with and question the TSB staff responsible for the administration of the fund.

Senior managers from the 2012 Biomedical Catalyst Scheme winners Absynth, Glide Pharma, Arecor, Pharminox, Domainex, Summit, GeneFirst and Pharmidex all attended these OBN events.

At the second Oxford event in October this year, entitled "Learning from the Winners, How to Succeed with the Biomedical Catalyst Scheme", OBN was the first organisation to call on the UK Government to extend and expand on the industry component of the Biomedical Catalyst to £2bn over 10 years, which will help maintain the UK bioindustry's number one position in Europe.

Having presented at three of the OBN events, Dr Helen Kuhlman, Lead Technologist, Medicines and Healthcare, TSB commented, "OBN events have provided a great opportunity to reach out to exciting businesses and talk with the people responsible for developing innovative healthcare propositions about their challenges and aspirations." 

Dr Jon Rees, CEO, OBN, commented, "OBN is delighted to work with the TSB in order to ensure that its members have the best chance of funding success.  Having identified an effective scheme to stimulate innovative R&D, we hope the UK Government will build on this commitment toward ensuring the scheme is of a scale and duration sufficient to maintain the UK bioindustry's number one position in Europe."

OBN's early and comprehensive efforts on the BMC are part of our facilitation of funding for the early-stage UK life science sector that in the last year has also included presentations by partners from the Syncona Fund, Index Ventures and NeoMed to our members. In addition, OBN will host the second City Investment Network event at Baker Botts in the City of London later today, and the BMC will chair a showcase scientific session of the winners from the BMC Scheme at next year's BioTrinity conference which will be held in Newbury from the 14th to the 16th of May, 2013.

About OBN

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs